Monitoring osteoporosis therapies

被引：21

作者：

Miller P.D. ^{[1
]}

机构：

[1] Colorado Center for Bone Research, Lakewood, CO 80227

来源：

Current Osteoporosis Reports | 2007年 / 5卷 / 1期

关键词：

Bone Mineral Density; Vertebral Fracture; Bone Turnover; Alendronate; Teriparatide;

D O I：

10.1007/BF02938621

中图分类号：

学科分类号：

摘要：

Postmenopausal osteoporosis (PMO) is a progressive disease of bone loss, fractures, or both. The progression of osteoporosis leads to increased mortality and morbidity and impairs quality of life. There are effective treatments that prevent bone loss, increase bone strength, and reduce fracture risk, improvement in persistence and adherence to therapy leads to better clinical outcomes. The management of PMO is facilitated by measuring surrogate markers of the efficacy of PMO treatments: 1) bone mineral density, 2) bone turnover markers, and 3) assessment of spinal integrity by vertebral fracture assessment by dual-energy x-ray absorptiometry. Appropriate use of markers measures the patient's baseline fracture risk and monitors response to treatments. Clinicians must interpret markers in the context of a patient's fracture risk and determine the effectiveness of therapy. Integrating these markers enhances overall patient care. The surrogate markers help the clinician to achieve the goal of managing PMO; attempting to manage PMO without markers reduces the clinical management to guesswork. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：38 / 43

页数：5

共 51 条

[1]

Lindsay R., Gallagher J.C., Kleerekoper M., Pickar J.H., Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women, Osteoporos Int, 16, pp. 372-379, (2005)

[2]

Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E., Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older, N Engl J Med, 337, pp. 670-676, (1997)

[3]

Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Et al., Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials, JAMA, 293, pp. 2257-2264, (2005)

[4]

Black D.M., Cummings S.R., Karpf D.B., Et al., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, pp. 1535-1541, (1996)

[5]

Harris S.T., Watts N.B., Genant H.K., Et al., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, JAMA, 282, pp. 1344-1352, (1999)

[6]

Chesnut III C.H., Skag A., Christiansen C., Et al., Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J Bone Miner Res, 19, pp. 1241-1249, (2004)

[7]

Chesnut III C.H., Silverman S., Andriano K., Et al., A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group, Am J Med, 102, pp. 267-276, (2000)

[8]

Neer R.M., Arnaud C.D., Zanchetta J.R., Et al., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 344, pp. 1434-1441, (2001)

[9]

Tosteson A.N., Grove M.R., Hammond C.S., Et al., Early discontinuation of treatment for osteoporosis, Am J Med, 115, pp. 209-216, (2003)

[10]

Miller N.H., Compliance with treatment regimens in chronic asymptomatic diseases, Am J Med, 102, pp. 43-49, (1997)

← 1 2 3 4 5 6 →